We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK and Alector Strike $2.2 Billion Deal to Develop Parkinson's, Alzheimer's Drugs
GSK and Alector Strike $2.2 Billion Deal to Develop Parkinson's, Alzheimer's Drugs
GlaxoSmithKline (GSK) and Alector have forged a $2.2 billion pact to develop monoclonal antibodies for treating Parkinson’s and Alzheimer’s diseases, among other neurological conditions.